PE62299A1 - THERAPEUTIC DERIVATIVES OF NAFTALENE - Google Patents

THERAPEUTIC DERIVATIVES OF NAFTALENE

Info

Publication number
PE62299A1
PE62299A1 PE00023098A PE00023098A PE62299A1 PE 62299 A1 PE62299 A1 PE 62299A1 PE 00023098 A PE00023098 A PE 00023098A PE 00023098 A PE00023098 A PE 00023098A PE 62299 A1 PE62299 A1 PE 62299A1
Authority
PE
Peru
Prior art keywords
6alkyl
hydrogen
6alkoxy
4alkyl
trifluoromethyl
Prior art date
Application number
PE00023098A
Other languages
Spanish (es)
Inventor
David Norman Deaton
Robert Blount Mcfadyen
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE62299A1 publication Critical patent/PE62299A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/68—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C229/70—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/47—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a compound of formula (I) wherein the groups N(R<3>) and R<4> are separated by at least 4 ring carbon atoms; R<1> represents a phenyl, naphthyl, phenoxymethyl, thiazolyl, pyridyl or pyrimidyl group, optionally substituted by one or more substituents selected from halogen, hydroxy, C1-6alkoxy, C1-6alkyl, nitro, cyano, hydroxymethyl, trifluoromethyl, NR<6>R<7>, and NHSO2R<6>; R<2> represents hydrogen or C1-6alkyl; R<3> represents hydrogen or C1-4alkyl; R<4> represents CO2R<6> or SO3H; R<5> represents one or more groups independently selected from hydrogen, C1-6alkyl, halogen, trifluoromethyl and C1-6alkoxy; n represents an integer from 1-6; R<6> and R<7> independently represent hydrogen or C1-4alkyl; or pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in the treatment of conditions susceptible of amelioration by an atypical beta-adrenoceptor agonist.
PE00023098A 1997-04-02 1998-03-27 THERAPEUTIC DERIVATIVES OF NAFTALENE PE62299A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9706707.8A GB9706707D0 (en) 1997-04-02 1997-04-02 Chemical compounds

Publications (1)

Publication Number Publication Date
PE62299A1 true PE62299A1 (en) 1999-07-07

Family

ID=10810177

Family Applications (1)

Application Number Title Priority Date Filing Date
PE00023098A PE62299A1 (en) 1997-04-02 1998-03-27 THERAPEUTIC DERIVATIVES OF NAFTALENE

Country Status (7)

Country Link
AR (1) AR012209A1 (en)
AU (1) AU7212598A (en)
GB (1) GB9706707D0 (en)
HR (1) HRP980171A2 (en)
MA (1) MA26478A1 (en)
PE (1) PE62299A1 (en)
WO (1) WO1998043953A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10326631A1 (en) * 2003-06-11 2005-01-05 Basf Ag Use of quinaldine and naphthalene derivatives as crystallization modifiers
ES2374165T3 (en) 2005-12-19 2012-02-14 Glaxosmithkline Llc AGONISTS OF THE X FARNESOID RECEIVER.
FR3041358B1 (en) * 2015-09-21 2017-11-24 Commissariat Energie Atomique ELECTROLYTE FOR ELECTROCHEMICAL GENERATOR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists

Also Published As

Publication number Publication date
MA26478A1 (en) 2004-12-20
HRP980171A2 (en) 1998-12-31
GB9706707D0 (en) 1997-05-21
WO1998043953A1 (en) 1998-10-08
AR012209A1 (en) 2000-09-27
AU7212598A (en) 1998-10-22

Similar Documents

Publication Publication Date Title
AP1687A (en) Therapeutic biaryl derivatives.
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
DE69932628D1 (en) HERBICIDES
NO20065494L (en) Fused quinoline derivatives and their use
RU95108387A (en) Diketopiperazine, process for preparing thereof, pharmaceutical composition, use of diketopiperazine
AU2661400A (en) Pyrazolopyridines
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
AU692090B2 (en) Novel 4,6-diarylpyrimidine derivatives and salts thereof
AU3015289A (en) 2&#39;-deoxy-5-fluorouridine derivatives
YU76401A (en) 1-amino triazolo(4,3-a)quinazoline-5-ones and or -5-thiones inhibiting phosphodieterase iv
DK0583485T3 (en) Ethanolamine derivatives with sympathomimetic and anti-pollakisuria effects
NO20000957L (en) Branched alkoxy-substituted 2-aminopyridines as NOS inhibitors
BG104447A (en) Biphenylamidine derivatives
ES2039221T3 (en) PROCEDURE FOR PRODUCING PIRIDAZINONE DERIVATIVES.
BR0209901A (en) Processes for the synthesis of 2,3-dihydro-1,4-dioxino- [2,3-f] quinoline derivatives
PE62299A1 (en) THERAPEUTIC DERIVATIVES OF NAFTALENE
WO2005053702A3 (en) Anti-inflammatory agents
PL361850A1 (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
WO2001022951A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AP2002002595A0 (en) Heterocyclic amide derivatives.
DK1000067T3 (en) Thiazolobenzoheterocyclic compounds, their preparation and drugs containing the compounds
AU2001259242A1 (en) Process for the preparation of chemical compounds
TR200100222T2 (en) Isoquinolines as urokinase inhibitors
DK0784973T3 (en) Quinoxaline derivatives for the treatment of tinnitus
WO2000050017A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal